Table 1.
Characteristics of 85 CML patients treated with ponatinib
| Sex | N° | % |
|---|---|---|
| Male | 47 | (55) |
| Female | 38 | (45) |
| Age at diagnosis, median years (range) | 53 | (23‐81) |
| Median follow‐up, median years (range) | 6.3 | (0.8‐25.9) |
| Leukocyte ×10 3 /uL, mean value (range) | 104 | (7‐500) |
| Hemoglobin g/dl, mean value (range) | 12.7 | (5.5‐16.7) |
| Platelet ×10 3 /uL, mean value (range) | 400 | (45‐1667) |
| BCR‐ABL transcript type | ||
| p210 | 83 | (97.6) |
| p190 | 2 | (2.4) |
| p230 | 0 | (0) |
| Splenomegaly | 48 | (56.5) |
| Sokal score | ||
| Low | 35 | (41.1) |
| Intermediate | 36 | (42.4) |
| High | 14 | (16.5) |
| Line of treatment | ||
| Second line | 23 | (27) |
| Third line | 37 | (43.5) |
| Fourth line | 25 | (29.5) |
| Ponatinib dose | ||
| 45 mg/day | 34 | (40) |
| 30 mg/day | 36 | (42.3) |
| 15 mg/day | 15 | (17.7) |
| Reason of switch | ||
| Inefficacy | 69 | (81.1) |
| Intolerance | 16 | (18.9) |
| Duration of ponatinib median months (range) | 28 | (3‐69) |